Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.62 |
| ▸ | SCD | O00767 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423860 | 1.00 | DRD2 (0.63) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL3640167 | 0.92 | DRD2 (0.59) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL12605572 | 0.92 | DRD2 (0.59) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL19691088 | 0.91 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL30364138 | 0.91 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL2424591 | 0.90 | DRD2 (0.58) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL1239171 | 0.87 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL6744630 | 0.87 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL7143252 | 0.87 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL30588460 | 0.87 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | claimed |
| JP-2006514009-A | — | — | 2006-04-27 | — | — | JP | claimed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | claimed |
| EP-1585751-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | Celmed Oncology (USA), Inc. (CA) | 2005-10-19 | — | — | EP | claimed |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | NEWBIOTICS, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| CN-119019383-A | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115974845-B | Preparation method of Ornitinib intermediate | 奥锐特药业股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-115175902-B | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-113179640-B | Nitrogen-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| EP-3197501-B1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-110698461-B | Preparation method of third-generation EGFR inhibitor | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-1998025898-A1 | SECO PRECURSORS OF CYCLOPROPYLINDOLINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998025898-A1 | SECO PRECURSORS OF CYCLOPROPYLINDOLINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998011101-A2 | CONDENSED N-ACLYINDOLES AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997007101-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | DRD2 4163/4885SLC6A4 2712/4885OPRM1 4385/4885 |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | DRD2 4328/4885SLC6A4 2950/4885OPRM1 4284/4885 |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | DRD2 3992/4885SLC6A4 4717/4885OPRM1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.